Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business...
Approved for use in the earliest symptomatic stages, Kisunla is the only once-monthly amyloid plaque–targeting therapy with evidence supporting tre...
Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...
Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...
New GMP facility for transfection reagents of French sub-group Sartorius Stedim Biotech in Illkirch Facility equipped to support next-generation techn...
Proprietary process reduces development timelines from 18 months to as little as 3, eliminates reliance on traditional plastic flatware, and offers rap...
The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored in Düsseldorf with the Innovation Award 2025 of the State ...
Booking Health, a global medical travel platform, announced the expansion of patient access to dendritic cell immunotherapy for recurrent glioblastoma, f...
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...
Two leaders in lipid nanoparticle (LNP) development have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-vira...
Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingw...
Scenic Biotech, a pioneer in modifier therapies for severe diseases, announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDA...
XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop...
Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to...
© 2025 Biopharma Boardroom. All Rights Reserved.
